Search

Displaying results 1001 - 1010 of 5300 in total
  1. Drug

    Recombinant stabilized RSV B prefusion F antigen

    go.drugbank.com/drugs/DB18714
    ApprovedInvestigational

    [L49555] Abrysvo was approved for the same indications in the EU in August 2023[L49565] and Canada in December 2023. … contrast to another RSV vaccine, [respiratory syncytial virus vaccine, adjuvanted] (Arexvy), Abrysvo is reconstituted with sterile water prior to injection and does not require the co-administration of an

  2. Drug

    Tofisopam

    go.drugbank.com/drugs/DB08811
    Investigational

    Although Tofisopam is not approved for sale in North America, it is approved for use in various countries worldwide, including parts of Europe.

  3. Drug

    Pentoxifylline

    go.drugbank.com/drugs/DB00806
    ApprovedInvestigational

    [A226608] Pentoxifylline has been marketed in Europe since 1972; PTX extended-release tablets sold under the trade name TRENTAL by US Pharm Holdings were first approved by the FDA on Aug 30, 1984, but

    International brands: An Ruo NingProducts: PENTOXIFILINA TABLETAS DE LIBERACIÓN PROLONGADA X 400MG
  4. Drug

    Fosigotifator

    go.drugbank.com/drugs/DB19409
    Investigational

    Fosigotifator is under investigation in clinical trial NCT05757141 (An Open-label Exploratory Study of ABBV-CLS-7262 Subjects With Vanishing White Matter Disease).

  5. Indication

    Alpha-1 Anti-trypsin Deficiency

    go.drugbank.com/conditions/DBCOND0066043
    Drugs: Recombinant alpha 1-antitrypsin
    Synonyms: AAT Deficiency, Alpha 1-Antitrypsin (AAT) Deficiency
  6. Drug

    Finerenone

    go.drugbank.com/drugs/DB16165
    ApprovedInvestigational

    [A236544] Spironolactone has low selectivity and affinity for the receptor; it dissociates quickly and can also have effects at the androgen, progesterone, and glucocorticoid receptors.

  7. Drug

    Nisevokitug

    go.drugbank.com/drugs/DB17561
    Investigational

    Nisevokitug is a monoclonal antibody targeted against transforming growth factor beta (TGFβ) under investigation in NCT04097821 (A Randomized, Open-label, Phase I/II Open Platform Study Evaluating Safety

  8. Drug

    Acetrizoic acid

    go.drugbank.com/drugs/DB09347
    ApprovedWithdrawn

    Acetrizoic acid presents the molecular formula of 3-acetamidol-2,4,6-triiodobenzoic acid[L1702] and it is the first monomeric ionic compound used as an X-ray contrast agent. … [L1704] Acetrizoic acid presents, in the FDA records, a category of drug substance with an inactive status.[L1703]

    Categories: X-Ray Contrast Media, Iodinated, Watersoluble, Nephrotropic, High Osmolar X-Ray Contrast Media
  9. Drug

    Moxifloxacin

    go.drugbank.com/drugs/DB00218
    ApprovedInvestigational

    Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for ...

    Mixtures: Dex-Moxi, Dex-Moxi PFProducts: MOXIFLOXACINA DOUBLE-E PHARMA
  10. Drug

    Ustekinumab

    go.drugbank.com/drugs/DB05679
    ApprovedInvestigational

    [A187346] The therapeutic use of the drug started in Canada, the US, and Europe since 2009 when it was first approved for the treatment of adult patients with moderate to severe plaque psoriasis and … including Wezlana,[L49071] Yesintek,[L52815] Selarsdi,[L52820] Otulfi,[L52825] and Pyzchiva[L52810] in the US, Jamteki (AVT04),[L49076] Steqeyma,[L52830] and Wezlana [L52073] in Canada, and Uzpruvo in the EU